4.50
price up icon6.13%   0.26
pre-market  Vorhandelsmarkt:  4.53   0.03   +0.67%
loading
Schlusskurs vom Vortag:
$4.24
Offen:
$4.26
24-Stunden-Volumen:
324.82K
Relative Volume:
0.76
Marktkapitalisierung:
$208.46M
Einnahmen:
$20.72M
Nettoeinkommen (Verlust:
$-100.84M
KGV:
-1.6917
EPS:
-2.66
Netto-Cashflow:
$-78.56M
1W Leistung:
+8.17%
1M Leistung:
+8.96%
6M Leistung:
-2.39%
1J Leistung:
-73.65%
1-Tages-Spanne:
Value
$4.21
$4.50
1-Wochen-Bereich:
Value
$4.145
$4.50
52-Wochen-Spanne:
Value
$2.235
$19.69

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
Firmenname
4 D Molecular Therapeutics Inc
Name
Telefon
(510) 505-2680
Name
Adresse
5858 HORTON STREET #455, EMERYVILLE
Name
Mitarbeiter
227
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-13
Name
Neueste SEC-Einreichungen
Name
FDMT's Discussions on Twitter

Vergleichen Sie FDMT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FDMT
4 D Molecular Therapeutics Inc
4.50 192.71M 20.72M -100.84M -78.56M -2.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-13 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-11-21 Eingeleitet Morgan Stanley Underweight
2024-09-23 Herabstufung Cantor Fitzgerald Overweight → Neutral
2024-04-15 Eingeleitet Barclays Overweight
2024-02-07 Fortgesetzt Goldman Buy
2023-10-26 Eingeleitet RBC Capital Mkts Outperform
2023-10-24 Eingeleitet Cantor Fitzgerald Overweight
2023-10-18 Hochstufung Leerink Partners Market Perform → Outperform
2023-07-05 Eingeleitet Chardan Capital Markets Buy
2023-01-30 Eingeleitet BMO Capital Markets Outperform
2022-11-18 Eingeleitet H.C. Wainwright Buy
2022-11-15 Hochstufung Goldman Neutral → Buy
2022-08-12 Herabstufung SVB Leerink Outperform → Mkt Perform
2022-06-22 Eingeleitet Jefferies Buy
2022-01-04 Eingeleitet SVB Leerink Outperform
2021-01-05 Eingeleitet BofA Securities Buy
2021-01-05 Eingeleitet Evercore ISI Outperform
2021-01-05 Eingeleitet Goldman Neutral
Alle ansehen

4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten

pulisher
02:22 AM

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.56 Average Price Target from Analysts - Defense World

02:22 AM
pulisher
Jul 22, 2025

4D Molecular Therapeutics Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is 4D Molecular Therapeutics Inc. a good long term investmentSignificant capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives 4D Molecular Therapeutics Inc. stock priceMarket-crushing stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionFree Popular Stock Recommendations - Newser

Jul 21, 2025
pulisher
Jul 19, 2025

What analysts say about 4D Molecular Therapeutics Inc. stockSuperior stock selection - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace

Jul 19, 2025
pulisher
Jul 18, 2025

Top Stocks for Aggressive Investors Top Growth StocksUnrivaled growth potential - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech

Jul 18, 2025
pulisher
Jul 17, 2025

4D Molecular Therapeutics’ Phase 3 Trial: A New Hope for Age-Related Macular Degeneration? - TipRanks

Jul 17, 2025
pulisher
Jul 15, 2025

What makes 4D Molecular Therapeutics Inc. stock price move sharplyHigh Return Potential - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How 4D Molecular Therapeutics Inc. stock performs during market volatilityAI Powered Stock Call - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Weiss Ratings Reiterates “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

4DMT Announces New Employment Inducement Grants - GlobeNewswire

Jul 11, 2025
pulisher
Jul 11, 2025

Late-Stage Biotech 4DMT Grants Significant RSU Package in Latest Strategic Hire - Stock Titan

Jul 11, 2025
pulisher
Jul 10, 2025

4D Molecular to layoff about 25% of workforce - MSN

Jul 10, 2025
pulisher
Jul 07, 2025

Promising Penny Stocks To Consider In July 2025 - simplywall.st

Jul 07, 2025
pulisher
Jul 06, 2025

4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at Chardan Capital - MarketBeat

Jul 06, 2025
pulisher
Jul 05, 2025

Chardan Capital Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 05, 2025
pulisher
Jul 04, 2025

4D Molecular Therapeutics Analyst Ratings: A Comprehensive Analysis - AInvest

Jul 04, 2025
pulisher
Jul 02, 2025

East Bay biotech to slash 25% of jobs after launching 2nd late-stage eye gene therapy study - The Business Journals

Jul 02, 2025
pulisher
Jul 02, 2025

4D Molecular Therapeutics Accelerates Wet AMD Trial, Cuts Jobs to Offset Costs - MarketScreener

Jul 02, 2025
pulisher
Jul 02, 2025

4DMT Announces Accelerated 4D-150 Phase 3 Development in - GlobeNewswire

Jul 02, 2025
pulisher
Jul 02, 2025

4D Molecular to layoff about 25% of workforce (FDMT:NASDAQ) - Seeking Alpha

Jul 02, 2025
pulisher
Jun 30, 2025

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jun 28, 2025
pulisher
Jun 17, 2025

Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025
pulisher
Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025
pulisher
Jun 16, 2025

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com

Jun 16, 2025
pulisher
Jun 16, 2025

Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts UTHR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts UBER FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts TYL FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Analysts Set Expectations for SHLS FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Predicts TG Therapeutics FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Analysts Set Expectations for SLNO FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Equities Analysts Offer Predictions for SPWR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Brokers Set Expectations for XENE FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Jun 10, 2025
pulisher
Jun 05, 2025

4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Jun 05, 2025

Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):